Arcturus Therapeutics Holdings Inc. (ARCT) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $15.94 (+0.63%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 4, 2026 | Yasmeen Rahimi | Piper Sandler | $25.00 | +56.8% |
| Aug 22, 2025 | Lili Nsongo | Leerink Partners | $54.00 | +238.8% |
| May 28, 2025 | Greg Harrison | Scotiabank | $32.00 | +100.8% |
| Mar 10, 2025 | Thomas Shrader | BTIG | $48.00 | +201.1% |
| Nov 11, 2024 | Whitney Ijem | Canaccord Genuity | $10.58 | -33.6% |
| Aug 6, 2024 | Whitney Ijem | Canaccord Genuity | $10.30 | -35.4% |
| Jul 2, 2024 | Ed Arce | H.C. Wainwright | $8.58 | -46.2% |
| May 31, 2024 | Yasmeen Rahimi | Piper Sandler | $20.02 | +25.6% |
| May 10, 2024 | Whitney Ijem | Canaccord Genuity | $12.30 | -22.8% |
| Mar 19, 2024 | Yale Jen | Laidlaw | $11.30 | -29.1% |
| Nov 2, 2022 | Gena Wang | Barclays | $25.00 | +56.8% |
| Nov 9, 2021 | Madhu Kumar | Goldman Sachs | $30.00 | +88.2% |
Top Analysts Covering ARCT
ARCT vs Sector & Market
| Metric | ARCT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +174.8% | +16187.0% | +19.5% |
| P/E Ratio | -3.69 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $3M | $6M | $10M | 4 |
| 2026-12-31 | $3M | $7M | $11M | 4 |
| 2027-03-31 | $5M | $10M | $16M | 4 |
| 2027-06-30 | $3M | $6M | $10M | 3 |
| 2027-09-30 | $9M | $21M | $33M | 3 |
| 2027-12-31 | $14M | $31M | $50M | 3 |
| 2028-12-31 | $55M | $139M | $456M | 6 |
| 2029-12-31 | $42M | $107M | $349M | 5 |
| 2030-12-31 | $67M | $170M | $557M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.78 | $-1.00 | $-0.29 | 3 |
| 2026-12-31 | $-1.80 | $-1.02 | $-0.29 | 6 |
| 2027-03-31 | $-1.77 | $-1.00 | $-0.29 | 3 |
| 2027-06-30 | $-1.99 | $-1.13 | $-0.32 | 5 |
| 2027-09-30 | $-1.56 | $-0.88 | $-0.25 | 3 |
| 2027-12-31 | $-1.22 | $-0.69 | $-0.20 | 6 |
| 2028-12-31 | $-6.92 | $-1.47 | $18.71 | 7 |
| 2029-12-31 | $-9.46 | $-2.39 | $-0.51 | 2 |
| 2030-12-31 | $-2.29 | $-0.58 | $-0.12 | 5 |
Frequently Asked Questions
What is the analyst consensus for ARCT?
The consensus among 1 analysts covering Arcturus Therapeutics Holdings Inc. (ARCT) is Buy with an average price target of $25.00.
What is the highest price target for ARCT?
The highest price target for ARCT is $54.00, set by Lili Nsongo at Leerink Partners on 2025-08-22.
What is the lowest price target for ARCT?
The lowest price target for ARCT is $8.58, set by Ed Arce at H.C. Wainwright on 2024-07-02.
How many analysts cover ARCT?
1 analysts have issued ratings for Arcturus Therapeutics Holdings Inc. in the past 12 months.
Is ARCT a buy or sell right now?
Based on 1 analyst ratings, ARCT has a consensus rating of Buy (2.00/5) with a +174.8% upside to the consensus target of $25.00.
What are the earnings estimates for ARCT?
Analysts estimate ARCT will report EPS of $-1.00 for the period ending 2026-09-30, with revenue estimated at $6M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.